Stock listing
Can-fite Biopharma Ltd.
Selected listing: CANF · TASE · ILA · IL
Can-fite Biopharma Ltd. (TASE:CANF), Health Technology. Latest release Sep 8, 2026: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress…
- Ticker
- TASE:CANF
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- TASE
- Currency
- ILA
About Can-fite Biopharma Ltd.
Can-fite Biopharma Ltd. is a public company listed on the Israeli market under the ticker CANF. Can-fite focuses on developing innovative therapies for various medical conditions.
Latest news from Can-fite Biopharma Ltd.
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
September 8, 2026
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
May 18, 2026
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
May 13, 2026
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
April 30, 2026
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
March 30, 2026
Events
Replays
Can-Fite Biopharma Ltd (CANF) Q3 2020 Earnings Call
Mon, Nov 30, 2020 · 09:15 AM ET
Watch
Research Can-fite Biopharma Ltd.
Can-fite Biopharma Ltd. company profile
View the public company page for Can-fite Biopharma Ltd. on 6ix.
Can-fite Biopharma Ltd. news
Read company news and market updates connected to Can-fite Biopharma Ltd..
Can-fite Biopharma Ltd. investor events
Find investor webinars, events, and replay context for Can-fite Biopharma Ltd..